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EARLY SEIZURE BLOCKADE: PREVENTING LONG-TERM EPILEPTIC ACTIVITY IN WAG/RIJ 
RATS.  April R. Levin1, Matthew L. Vestal1, Frederick Wang1, Kathryn Giblin1, Crystal Paul-
Laughinghouse1, Tim Rice1, Anne M.  Phadke1, Davender S. Khera1, Joshua P. Klein1, John Mission1, 
Chhitij Bashyal1, Joshua Motelow1, Hrachya Nersesyan1, R.K. Agarwal1, Dario J. Englot1, Ulrich 
Schridde1, Steven G. Waxman1, Hal Blumenfeld1,2,3.  Department of 1Neurology, 2Neurobiology, and 
3Neurosurgery, Yale University School of Medicine, New Haven, CT. 
 
The purpose of this study was to determine how early seizure blockade with ethosuximide (ESX) would 
influence ion channel expression and long-term spike-wave discharge (SWD) activity in epileptic WAG/Rij 
rats.  The goal was to elucidate the question “Do seizures beget seizures?” in a genetically prone model and 
if so, to attempt to interrupt this cycle by early intervention.  In our first experiment, we used 
immunocytochemistry to determine the effect of ESX on cortical expression of ion channels in treated and 
untreated WAG/Rij rats and age-matched Wistar controls.  This experiment revealed that treatment with 
ESX blocked the upregulation of Nav1.1 and Nav1.6 as well as the downregulation of HCN1 that is 
associated with epileptic activity in rats (p < .05).  In a second experiment, WAG/Rij rats were divided into 
3 groups: untreated (H2O), temporary early treatment (ESX 4 month), and continuous early treatment (ESX 
continuous), and SWD activity was measured by electroencephalogram (EEG) at various timepoints.  This 
second experiment revealed that animals in the ESX 4 month group spent less percent time in SWD (0.242 
± .068 SEM) than animals in the H2O group (0.769 ± .060 SEM, p < .001), although they spent slightly 
more percent time in SWD than animals in the ESX continuous group (0.020 ± .065 SEM, p = .003).  This 
effect was predominantly due to seizure number, and average seizure duration did not vary among the three 
groups.   Additionally, power spectrum analysis revealed a significant correlation when the difference 
between power spectra for H2O and ESX 4 month rats was compared to the power spectrum of a seizure 
(Pearson correlation equals 0.955, 2-tailed significance < .000000001), suggesting quantitatively that 
seizures were reduced by temporary early treatment.  This suggests that early prevention of SWD may 
reduce the burden of seizures later in life, and that possibilities for prevention of genetic absence epilepsy 
should be further investigated. 
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Epilepsy constitutes an important medical issue.  120 in 100,000 people seek 
medical attention for newly recognized seizure disorders each year, and among this 
population there is tremendous variability in seizure types and manifestations, treatments 
and side effects, and associated comorbidities.  Epilepsy is especially prevalent and often 
severe in children, with approximately 0.5-1% of children affected with the disorder [1].   
An important issue in the treatment of children with epilepsy is not only how best 
to treat the immediate seizures, but how treatment and seizures will affect brain 
development and hence propensity for seizures later in life [2-4]. A number of in vitro 
and in vivo studies have been done in a variety of seizure models to investigate the 
question, “Do seizures beget seizures?” Many of these models involve the experimental 
induction of seizure activity, and they do suggest that either the induction of a seizure or 
the seizure itself may increase the likelihood of epileptic activity later in life [2, 5-7].  
However, in order to determine whether seizure activity alone can increase the propensity 
for further seizures, it is necessary to use a model of spontaneously occurring epilepsy 
[8], and to determine whether prevention of early seizure activity can help to prevent the 
development of epilepsy, known as epileptogenesis. 
 
Animal Models 
 A number of animal models of spontaneously occurring epilepsy are available, 
including Wistar Albino Glaxo from Rijswijk (WAG/Rij) rats [9-12], Genetic Absence 
Epilepsy Rats from Strasbourg (GAERS) [7, 12, 13], and epileptic beagles [7].  Both rat 
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models were bred for spontaneous absence seizures from the Wistar rat strain, but the 
underlying genes for the epilepsy in these rats are not known [14-16].  Numerous strains 
of mice also exhibit spike-wave discharges (SWD) characteristic of absence epilepsy, and 
the question of whether seizures beget seizures has been studied in some of these mouse 
models.  For example, previous studies in tottering mice have shown network burst 
abnormalities which are more pronounced during development than at adulthood, 
suggesting that these abnormalities do not represent a secondary consequence of repeated 
seizures [17].  However, this experiment studied paroxysmal depolarizing shifts in 
response to elevated extracellular potassium in vitro as opposed to spontaneous seizure 
activity in vivo, and did not examine the effects of seizure blockade.  Therefore, this 
experiment suggested a mechanism for increased seizure susceptibility during 
development but did not rule out the possibility that seizure activity could beget further 
seizures by other mechanisms.  Along these lines, short-term seizure blockade with ESX 
after seizure onset in stargazer mice was not found to alter intermediate early gene 
protein (IEGP) expression associated with mossy fiber sprouting in induced seizure 
models [18]; however, this study also showed that IEGPs are not an obligatory step in 
mossy fiber sprouting in absence seizures, and the ESX treatment examined here was 
short-term and was not given prior to seizure onset.  Additionally, in “tottering,” 
“stargazer,” and numerous other strains of mice exhibiting SWD characteristic of absence 
epilepsy, including spontaneously mutated “lethargic,” “ducky,” “mocha 2j,” “slow-wave 
epilepsy,” “coloboma,” “leaner,” “rolling Nagoya,” and “rocker” and HCN2 knock-out 
mice, SWD are associated with severe motor abnormalities typically associated only with 
less common forms of absence epilepsy in humans [15, 19-21].   More recently, the 
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genetic basis of spike-wave seizures was also characterized in C3H/He mice, which do 
not exhibit any brain or motor abnormalities [15].  In a study of GAERS rats, 
levetiracetam treatment beginning one week prior to seizure onset did not prevent 
expression of SWD during adulthood; however, again in this study ESX treatment was 
short-term and was stopped before adulthood [22]. 
Among the models of spontaneous absence epilepsy, WAG/Rij rats are 
considered to have “face validity” as a model for human absence epilepsy.  This is based 
on the presence of SWD concurrent with decreased responsiveness, preferential 
occurrence of SWD during transitional states between sleep and waking, modulation of 
SWD by physical and mental activity, effect of antiabsence drugs (except lamotrigine), 
and inheritability, all of which are seen in human absence epilepsy as well [11].  A major 
difference between this model and human absence epilepsy is that absence seizures in 
WAG/Rij rats appear after puberty (around age 2-3 months) and worsen throughout life, 
whereas in humans the seizures generally occur before puberty and then disappear or 
convert to more severe forms of epilepsy [11, 21, 23-26].  Of note, GAERS rats develop 
SWD earlier, after approximately 30 days of life [21].  Another major difference is that 
SWD occur at a frequency of 7-10 Hz in the rat and 3-4 Hz in the human [10, 23].  
Notably, the frequency of SWD in mouse models of absence epilepsy is also higher (5-7 
Hz) than in humans [21]. 
Two types of SWD are known to occur in WAG/Rij rats.  The first type is seen 
during both sleep and wakefulness, lasts at least 1 second, shows a train of sharp spikes 
and slow waves directed upwards with a frequency of 7.5 to 9.5 Hz and an amplitude of 
at least twice the background, occurs at an average of 18 discharges per hour depending 
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on the age of the rat, and is accompanied by behavioral concomitants reminiscent of 
human absence seizures.  The second type occurs almost exclusively during wakefulness, 
lasts at least 0.5 seconds, shows opposite polarity of the spikes and another position to the 
waves compared to type I, has a frequency ranging from 7.6 to 8.3 Hz and an amplitude 
of at least twice the background, occurs at an average of 14 discharges per hour, and is 
not accompanied by behavioral correlates [9].   
The exact underlying genes controlling SWD in WAG/Rij rats remain unknown.  
Genetic control of SWD was recently mapped to chromosome 5 for type I SWD and 
chromosome 9 for type II SWD [14].  One dominant gene does appear to determine the 
occurrence of type 1 SWD in WAG/Rij rats, but multiple other background genes likely 
manipulate the number and duration of the SWD [27]. 
 SWD in rats, as in humans, occur most often during passive wakefulness or light 
slow-wave sleep, less often during active wakefulness, and rarely during slow wave and 
rapid eye movement (REM) sleep [11, 23, 28, 29].  As in humans, slow-wave sleep in 
rats is characterized by large-amplitude, low-frequency, irregular delta waves, whereas 
waking is associated with high-frequency, low-amplitude beta waves.  Interestingly, both 
rats and humans can be aroused during SWD.  Rats have been shown to be more likely to 
be aroused by a conditioned stimulus than an unconditioned stimulus, suggesting that 
information continues to flow through the brain even during SWD [10]. 
 
Pharmacology 
 A number of pharmacological agents have been used to treat absence seizures.  
Ethosuximide (ESX), valproate, and trimethadione all act as antiabsence drugs in both 
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humans and rats, whereas anticonvulsant drugs such as carbamazepine and 
diphenylhydantoin have no effect or even worsen absence seizure activity [11, 30].  
Currently, ESX is considered a first choice anti-absence drug [31].   
 The exact mechanism of ESX in blocking SWD is controversial.  Although 
blockade of thalamic T-type Ca2+ channels is often cited as the most likely mechanism 
[32], a reduction of nonactivating Na+ current and Ca2+-activated K+ current in thalamic 
and cortical neurons is also likely to contribute to the therapeutic action of ESX [33]. 
 
Absence seizures: Classification 
Seizures are generally classified as focal (involving only part of the brain) or 
generalized (involving the whole brain) [26, 34].  Absences are a type of generalized 
seizure, and typical absences demonstrate clinical impairment of consciousness and 3-
4Hz SWD on EEG [34].  They are most commonly associated with childhood absence 
epilepsy (CAE), which peaks at age 6-7 [26] and remits by adolescence in 70% of 
patients [21].  Other idiopathic generalized epilepsies associated with absence include 
juvenile absence epilepsy (JAE), in which onset peaks at puberty.  Absences tend to be 
less severe than in CAE, but the disorder is associated with infrequent myoclonic jerks 
and generalized tonic-clonic seizures.  Additionally, juvenile myoclonic epilepsy (JME) 
demonstrates the same seizure types and age of onset as JAE, but the myoclonic jerks are 
more severe than the absences in this syndrome.  Cryptogenic or symptomatic epilepsies 
involving absence have been identified as well, including myoclonic absence epilepsy, 
Lennox-Gastaut syndrome, and epilepsy with continuous spike-waves during slow sleep 
[26].   
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Mutations of several genes, including those encoding for various GABA, 
glutamate, acetylcholine, sodium, potassium, and calcium channels have been associated 
with some cases of  familial CAE, JAE, and JME [21, 35].  Additionally, it has been 
suggested that mouse models of absence and ataxia may be representative of combined 
absence and ataxia syndromes in humans [21].   Although 16-45% of patients with CAE 
report of positive family history, penetrance is incomplete, with concordances of 75-80% 
among monozygotic twins and 33% among first-degree relatives [21].  The majority of 
human absence epilepsies are therefore likely due to complex genetic inheritance factors, 
and several studies are currently underway to investigate the genotype phenotype 
correlations in absence and other human epilepsies [35, 36]. 
 
Absence seizures: Generation and maintenance 
 Although absence seizures are considered to be generalized, it is known that 
specific cortico-thalamic networks play an important role in the generation and 
maintenance of these seizures, while other regions are relatively spared  [11, 37, 38].  
Although debate continues about the region of seizure onset in humans, onset in 
WAG/Rij rats was recently localized to the facial region of the somatosensory cortex.  
However, after the first 500 msec of a seizure in WAG/Rij rats, cortical and thalamic 
sites interact bi-directionally, with the direction of coupling varying throughout the 
seizure [38, 39].  Similarly in GAERS rats, microinfusion of ESX into the peri-oral 
region of the primary somatosensory cortex (S1po) produces an immediate cessation of 
seizure activity, whereas infusion of ESX into the thalamus produces only a modest and 
delayed reduction in SWD [40].  
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Multiple ion channels are likely to be involved in the initiation and maintenance 
of absence seizures [41, 42]. Studies in collaboration with our lab showed that the 
expression of messenger ribonucleic acid (mRNA) and protein for the sodium channels 
Nav1.1 and Nav1.6 is upregulated in the WAG/Rij epileptic cortex compared to non-
epileptic controls [24], and seizure activity has been shown to induce changes in sodium 
channels in non-absence seizures as well [43-48].  Similarly, alterations in the cation 
channel HCN1 and its depolarizing current Ih have been associated with absence seizures 
in WAG/Rij rats [49, 50], GAERS rats [51], and stargazer mice [52].   
Such results beg the question of whether the changes in channel level are a cause 
or an effect of seizure activity.  To answer this question, we first conducted an 
experiment in which ESX was used to block spontaneous seizure activity in WAG/Rij 
rats, and the effects on channel expression were measured.  If blocking seizures could 
block alteration in channel levels, and if alteration in channel levels is associated with 
alterations in neuronal bursting, the question follows whether early seizure blockade 
might break a self-reinforcing cycle in which seizures alter channel levels, resulting in 
increased seizure susceptibility.  In our second experiment, therefore, we studied the 




Hypothesis and Specific Aims 
The goal of our experiments was to investigate the broad question, “Do seizures 
beget seizures?”  Given that Nav1.1 and Nav1.6 are known to be upregulated in 
WAG/Rij cortex [24] and HCN1 is known to be downregulated in this region [49, 50], 
we hypothesized that treatment with ESX would block these changes in ion expression.  
As a corollary, we hypothesized that treatment with ESX during the usual period of 
seizure onset in these rats would decrease SWD even once the ESX was withdrawn. 
 To investigate these hypotheses, our first aim was to determine total seizure time 
in treated and untreated WAG/Rij and Wistar rats to quantify the effect of ESX on 
blockade of SWD activity.  We then planned to determine the expression of Nav1.1, 
Nav1.6, and HCN1 in the cortices of these rats.  Finally, we aimed to determine the effect 
of early temporary treatment with ESX by using electroencephalography (EEG) to 
quantify seizure frequency and duration in treated, untreated, and temporarily treated 
WAG/Rij rats, and to use power spectrum analyses to determine quantitatively how these 









The WAG/Rij rat strain originated from the Radiobiological Institute TNO in 
Rijswijk, and a colony is maintained at Yale University.   Non-epileptic female Wistar 
rats were obtained from Charles River Laboratories in Wilmington, MA.  These rats were 
screened by EEG and were not included in the study if significant SWD activity was 
noted.  Animals were all female, were housed in groups of two or three and were kept on 
a 12-hour light/dark cycle with unlimited access to food and water, in accordance with 
NIH guidelines for the care and use of laboratory animals.  Animal protocols were all 
approved by the Yale University Institutional Animal Care and Use Committee. 
In the treated groups, ESX was administered orally at a dose of 300 mg/kg/d by 
adding it to the drinking water beginning at the time of weaning (p21).  Based on pilot 
measurements, we determined that the rats drink approximately 120 cc/kg/d, and drink 
slightly more (~200 cc/kg/d) in the first 1.5 months.  Therefore, ESX 300mg/kg/d was 
given using 250mg/5ml syrup (Pharmaceutical Associates, Inc. Greenville, SC) by 
adding 3cc of syrup per 100cc H2O for p21 through p45, and 5cc per 100cc H2O for p45 
onward.  Pilot experiments showed that lower doses of ESX (100 - 200 mg/kg/d) did not 
consistently block SWD, whereas higher doses (400 mg/kg/d) caused significant lethargy 
and gait ataxia.  The dose of 300 mg/kg/d was effective in completely blocking SWD, 
and was also well tolerated without any side effects of lethargy, ataxia, or reduced food 
intake.  Water bottles were coated on the outside with black paint since the medication is 
light-sensitive, and the medication in the bottles was replaced at least weekly to ensure 
that therapeutic doses were continuously available. 
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In experiment #1, a total of 31 animals were used.  Epileptic WAG/Rij rats (n=15) 
were compared to age-matched Wistar controls (n=16), and each group was subdivided 
into those treated with ESX (n=8 Wistar, n=8 WAG/Rij) and those not treated (n=8 
Wistar, n=7 WAG/Rij).  The treated group received ESX beginning at weaning (p21) 
(Fig. 1A).   
For experiment #2, a total of 37 animals were used.  In the first group, called 
“H2O” (n=13), rats received no ESX at any point.  In the second group, called “ESX 4 
months” (n=11), rats had ESX added to their water bottles at weaning (p21) and 
continued for 4 months, at which point ESX was discontinued and rats resumed receiving 
plain water.  In the third group, called “Continuous” (n=13), ESX was given from 





Figure 1.  (A) Experiment I: Effects of early ESX on cortical ion channel expression. Rats were divided 
into 4 groups: Wistar nonepileptic rats receiving no treatment (NE control H2O), Wistar nonepileptic rats 
receiving treatment (NE control ESX), WAG/Rij rats receiving no treatment (WAG/Rij H2O), and 
WAG/Rij rats receiving treatment (WAG/Rij ESX).  Rats in the ESX groups began receiving ESX at 
weaning (p21).  At age 5 months, 6-hour EEG was recorded for each rat, followed by sacrifice for 
immunostaining.  (B) Experiment II: Effects of early ESX on seizure development.  WAG/Rij rats were 
divided into 3 groups: H2O, ESX 4 months, and ESX continuous.  Rats in the H2O group received no ESX 
at any point.  Rats in the ESX 4 months group began receiving ESX at weaning (p21) and continued for 4 
months until a baseline recording was completed (-1d), at which point they resumed receiving plain water 
for the remainder of EEG recordings (1, 14, 30, 60, and 90 days following ESX withdrawal).  Rats in the 
ESX continuous group began receiving ESX at weaning (p21), and continued throughout the duration of all 
EEG recordings. White bars = Rat receiving plain H2O; Black bars = Rat receiving ESX 300mg/kg/d. 
 
EEG Recordings 
 Electrodes were implanted at age 5 months for experiments #1 and #2.  For 
implantation of electrodes, animals were deeply anesthetized with intramuscular 
ketamine (100mg/kg), xylazine (5.2mg/kg) and acepromazine (1.0mg/kg) and placed in a 
stereotactic frame (David Kopf Instruments, Tujunga, CA).  Level of anesthesia was 
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measured by respiration, heart rate, glabrous skin perfusion, and response to foot pinch.  
Small burr holes were made in the skull without disturbing the dura and tripolar 
electrodes (Plastics One, Roanoke, VA) were secured to the skull using 1.60-mm 
stainless steel screws (Plastics One).  EEG recording electrodes were placed at AP +2.0, 
ML +2.0 mm and AP -6.0, ML +2.0mm.  A ground electrode was placed in the midline 
over the cerebellum.  Dental acrylic (Henry Schein Inc, Indianapolis, IN; Lang Jet 
Denture Repair Acrylic) was used to fix the electrode unit in place. 
 Continuous EEG data was recorded from awake-behaving rats between 10:00 AM 
and 4:00 PM (light cycle).  For experiment #1, following a 1-week recovery period after 
electrode implantation, EEG was recorded for 2 hours/day over a consecutive 3-day 
period for each animal, for a total of 6 hours of recording time per animal.  For 
experiment #2, at least 3 hours of baseline EEG was recorded at the following time 
intervals in the ESX 4 months group and age-matched controls in the H2O and ESX 
continuous groups: 1 day prior to stopping ESX; and then 1 day, 14 days, 30 days, 60 
days, and 90 days after stopping ESX. 
EEG signals were recorded via commutator (Plastics One, Inc.) using a Grass CP 
511 amplifier (Grass-Telefactor, Astro Med, West Warwick, RI), with band pass filter 
settings of 1 to 300 Hz.  Signals were digitized at a sampling rate of 1 kHz with a 
National Instruments USB-6008 A/D converter and LabView 7.1 software (National 
Instruments Ltd.), and analyzed using Spike2 software (Cambridge Electronic Design, 
Cambridge, UK).   
Start and end times of all SWD were marked by visual inspection of EEG 
recordings in both experiments.  Inspection was done by a total of five trained observers, 
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blinded to the experimental group and time point of each analysis.  Criteria for marking 
SWD included trains of rhythmic sharp spikes and slow waves with a frequency of 7-8 
Hz, lasting at least 1 second, with a peak-to-peak amplitude at least twice the 
background.  In experiment #1, for each experimental group, percent time spent in SWD 
was then calculated as (sum of SWD interval durations/total recording time).  
For experiment #1, where the goal of EEG recordings was simply to determine 
whether or not ethosuximide was effectively blocking SWD (i.e. a binary decision), we 
included all EEG data from a given file, as long as most of the file was free from artifact 
and from slow wave sleep (which obscures SWD).  For experiment #2, where precise and 
quantitative measurement of SWD duration and frequency was critical, all data files were 
subdivided by marking segments of “usable” (awake, artifact-free) and “unusable” 
(artifact or slow wave sleep) data .   More specifically, unusable data was defined as that 
in which slow-wave sleep (1-3 Hz, large amplitude waves or spindles) or signal-
obscuring artifact occurred for more than 75% of a 40-second period.  Since blocks of 
unusable data were required to last at least 40 seconds, this meant that any interruptions 
of the unusable data (i.e., segments of usable data) had to occur within the 40 second 
block and not on either end..  Usable data was defined as lack of artifact or large 
amplitude irregular slow activity on EEG occurring for >50% of a 40-second block, with 
blocks of unusable data allowed to be on the ends.  Blocks of usable data were therefore 
required to last >20 seconds.  Any SWD occurring during unusable time were recorded 
but were not included in further analyses.  For each experimental group at each time 
point, data was analyzed for percent of usable time spent in SWD, average number of 
seizures per hour of usable time, and average seizure duration.   
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Additionally, for each experimental group at each time point, aggregate power 
spectra were run for all seizures using Spike2, with programming done by Cambridge 
Electronic Design (Cambridge, England).  Aggregate power spectra were also run for 
usable time, and any data files noted by the reader to have more than very little artifact 
were not included in the power spectral analyses. 
For experiment #2, all statistical analyses for percent time in SWD, seizure 
number, and seizure duration were run in SPSS (v. 14, SPSS Inc., Chicago, Il, USA) 
using one-way ANOVA or MANOVA for repeated measures with Wilks’ Lambda 
multivariate analysis, followed by Games-Howell posthoc analyses if appropriate.  The 
between factor for all analyses was group (H2O, ESX 4 months, ESX continuous), and 
the within factor was time (-1d, 1d, 14d, 30d, 60d, 90d).  A p < .05 was regarded as 
significant.   
For analysis of power spectra, differences were assessed in SPSS by Pearson 
correlation.  A significance (2-tailed) value < .01 was regarded as significant. 
 
Perfusion  
When recordings were complete, rats were deeply anesthetized with 
ketamine/xylazine (80/5 mg/kg) given intraperitoneally, using a #26 needle.  The skin 
was then incised and the heart exposed.  For animals treated with ESX until perfusion, 
3ml of blood was drawn from the inferior vena cava at this time, transferred into a K2 
EDTA (3.6mg) BD Vacutainer, and centrifuged for 10-12 minutes at a speed of 1000x.   
Supernatant was then transferred to a CryoTube vial, placed on dry ice, and sent to 
National Medical Services (Willow Grove, PA) for measurement of ESX levels. 
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To perfuse, the inferior vena cava was incised to allow blood to escape, and an 
18.5 gauge needle attached to a perfusion pump with 0.01 M phosphate buffer solution 
(PBS) was then inserted into the left ventricle and clamped against the heart muscle.  
Perfusion with PBS was continued at 8ml/min until liquid in the tubing became clear (5 
minutes).  Perfusion was then switched to 4% cold buffered Paraformaldehyde (PFA) and 
continued until muscles were stiff (10-15 minutes).  Rats were then decapitated, skin was 
removed with a scalpel and skull was removed with a bone crusher.  Exposed brain was 
postfixed and cryoprotected in 30% sucrose solution. 
 
Immunocytochemistry 
For experiment #1, coronal sections (10μm) of the cerebral hemispheres were cut 
at AP +0.0, ML +6.0mm using the pial surface and deep white matter border as 
anatomical landmarks to obtain layers II-III of barrel somatosensory cortex, previously 
shown to have altered levels of Nav1.1 and Nav1.6 mRNA and protein in epileptic 
WAG/Rij compared to nonepileptic Wistar rats [24].  Bilateral sections were obtained, 
and data from both hemispheres was combined.  The sections were mounted onto slides 
and incubated in blocking solution (5% normal goat serum and 1% bovine serum albumin 
in phosphate buffer solution (PBS)) with 0.1% Triton X-100 and 0.02% sodium azide at 
room temperature for 30 minutes.  Serially consecutive slices with identical preparations 
were then incubated with subtype-specific antibodies to sodium channel α-subunit 
Nav1.1 (residues 465-481, 1:100 dilution, Alomone, Jerusalem), sodium channel α-
subunit Nav1.6 (residues 1042-1061, 1:100, Alomone, Jerusalem) and HCN1 (Chemicon 
rabbit anti-rat, 1:100, Temecula, CA) overnight at 4°C.  Slides were then washed in PBS, 
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incubated with biotinylated goat anti-rabbit serum (1:1000, Sigma) in blocking solution 
for 3h, washed again in PBS, incubated in avidin-horse radish peroxidase (1:1000, 
Sigma) in blocking solution for 3h, washed again in PBS, and incubated with goat anti-
rabbit IgG-Cy3 (1:2000, Amersham, New Jersey).  Immunofluorescence signal was 
detected using fluorescein illumination (emission wavelength 516-565 nm). 
A Nikon Eclipse TE300 light microscope was used for sample observation, and 
quantitative microdensitometry of immunostaining signals was obtained using IPLab v3.0 
Image Processing software (Scanalytics, Fairfax, VA).  Signal intensities were 
determined by outlining individual cortical neurons, and IPLab integrated densitometry 
functions were used to calculate mean signal intensities.  Results from identical regions 
and layers of cortex in WAG/Rij and Wistar rats, both treated (ESX) and untreated 
(H2O), were processed in parallel.  Immunopositivity was quantified by averaging 
multiple counts within a defined area (1.9 x 104 μm2) within layers II-III of barrel 
somatosensory cortex.  Only neurons with distinct borders whose nuclei fell within the 
plane of section were analyzed.  Approximately 50 neurons were analyzed for each 
antibody (Nav1.1, Nav1.6, and HCN1) per animal.  Analysis of neurons from left versus 
right somatosensory cortex showed no significant difference in level of expression within 
each group of rats, so these data were combined. 
For experiment #1 (immunocytochemistry), differences were assessed by one-
way ANOVA, followed by Bonferroni posthoc analyses if appropriate.  A p < .05 was 




 For experiment #1, the writer assisted in performing EEG recordings and 
maintaining consistent delivery of ESX to experimental animals, analyzed EEG data, and 
prepared figures.  For experiment #2, the writer analyzed 58% of the EEG data, managed 
and organized analyses completed by other observers, ran all power spectra, completed 





Examples of typical recordings from WAG/Rij rats treated with ESX and 
untreated are shown in Fig. 2A.  In the animals we studied, ESX treatment in WAG/Rij 
rats decreased the percent time spent in SWD to the level of nonepileptic (NE) Wistar 
controls (Fig 2C).  Mean percent times spent in SWD were 0.004 ± .002 SEM for NE 
control ESX, 0.095 ± .032 for NE control H2O, 0.100 ± .035 for WAG/Rij ESX, and 
0.771 ± .142 for WAG/Rij H2O.  ANOVA with post-hoc Bonferroni analyses showed 
significant differences between WAG/Rij H2O and all other groups (p < .001).  No other 
between-group differences were significant.  Notably, NE controls and WAG/Rij rats 
treated with ESX all spent a small amount of time in SWD, and treatment with ESX in 
Wistar controls did not significantly alter the time spent in SWD.  ESX levels drawn from 
blood prior to perfusion showed an average of 87.7 ± 9.8 SEM µg/ml for all treated 




Figure 2 Effect of ESX on SWD activity. (A) Example of SWD activity in untreated (H2O) WAG/Rij rats 
(bottom trace) with an example of typical SWD at higher gain (top trace).  (B) Example of SWD in 
WAG/Rij rats treated with ESX.  (C) Mean percent time spent in SWD for each experimental group.  Data 





Immunocytochemical experiments using subtype-specific antibodies for Nav1.1, 
Nav1.6, and HCN1 have previously shown that Nav1.1 and Nav1.6 are up-regulated in 
layer II-IV cortical neurons of barrel somatosensory cortex of WAG/Rij rats compared to 
Wistar rats (Klein 2004) [24], and that HCN1 is downregulated in this region [49, 50].    
Fig. 3A-L show staining of the barrel somatosensory cortex with antibodies for HCN1 
(Fig. 3A-D), Nav1.1 (Fig. 3E-H), and Nav1.6 (Fig. 3I-L).  These results demonstrate that 
in WAG/Rij rats treated with ESX, the levels of these proteins return to that in treated 
and untreated Wistar rats.  Quantification of these data (Fig. 3M) demonstrates that there 
is a significant increase in Nav1.1 and Nav1.6 protein and a significant decrease in HCN1 
in barrel somatosensory cortex of untreated WAG/Rij rats (p < .001, ANOVA with post-
hoc Bonferroni adjustment).  There is no significant difference in the levels of these 
proteins between Wistar rats and treated WAG/Rij rats.  Mean optical intensity for each 
group is listed as follows (Table 1): 
 
  
Mean Std. Error 
Nav1.1 NE control H2O 9.07 1.90 
  NE control ESX 6.73 1.03 
  WAG/Rij H2O 23.93 1.88 
  WAG/Rij ESX 4.82 0.76 
Nav1.6 NE control H2O 7.52 1.06 
  NE control ESX 10.53 2.34 
  WAG/Rij H2O 20.09 1.84 
  WAG/Rij ESX 7.73 1.08 
HCN1 NE control H2O 18.55 3.07 
  NE control ESX 20.16 3.07 
  WAG/Rij H2O 3.68 0.27 
  WAG/Rij ESX 21.05 3.89 
Table 1.  Quantification of mean optical intensity for each channel antibody (Nav1.1, Nav1.6, and HCN1) 
for nonepileptic Wistar control rats receiving no treatment (NE control H2O), nonepileptic Wistar control 
rats receiving ESX (NE control ESX), WAG/Rij rats receiving no treatment (WAG/Rij H2O), and 





Figure 3.  Effect of ESX on ion channel expression.  (A-L) Immunostaining of layers II-III of barrel 
somatosensory cortex in each experimental group for HCN1 (A-D), Nav1.1 (E-H), and Nav1.6 (I-L).  
Clockwise from top left for each ion channel: NE control H2O, NE control ESX, WAG/Rij ESX, WAG/Rij 
H2O. (M) Quantification of ion channel protein expression in barrel somatosensory cortex by optic 
densitometry.  WAG/Rij H2O rats (n=7) show a significant increase in Nav1.1 (white bars) and Nav1.6 
(gray bars), and a significant decrease in HCN1 (black bars) protein levels compared to that in Wistar NE 
control H2O (n=8) and NE control ESX (n=8) rats.  WAG/Rij rats treated with ESX (n=8) show protein 
levels of Nav1.1, Nav1.6, and HCN1 that is not significantly different from that in NE Wistar rats.  Data is 
plotted as mean ± SEM, * = p < .05, ANOVA with post-hoc Bonferroni analyses. 
 
Experiment 2 
 Figure 4 shows the effect of early ESX treatment on the percent time spent in 
SWD, as well as the number and duration of seizures.  Once treatment was discontinued, 
we observed a marked group effect for percent time in SWD over the course of 90 days 
(F2,31 = 38.197, p < .001).  The Games-Howell posthoc test revealed that rats in the ESX 
4 month group spent significantly less percent time in SWD (0.242 ± .068 SEM) 
compared to untreated rats (0.769 ± .060 SEM, p < .001), although they do spend more 
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percent time in SWD than rats in the ESX continuous treatment group (0.020 ± .065 
SEM, p = .003). 
Repeated-measurements MANOVA revealed a time effect (F5,24 = 5.335, p = 
.002), indicating that percent time in SWD was altered depending on the timepoint of the 
EEG recording.  This was expected based on previous observations [24].  Additionally, 
the repeated-measurements MANOVA revealed a time by group effect (F10,48 = 4.240, p 
< .001), indicating that the pattern of change over time in percent time in SWD differed 
between treatment groups. 
Percent time spent in SWD is the product of number of seizures and average 
seizure duration per unit of time.   Notably, for seizure number there is a group effect 
(F2,31 = 42.818, p < .001), a time effect (F5,24 = 6.128, p = .001), and a time by group 
effect (F10,48 = 4.56, p < .001); number of seizures per hour is 4.172 ± .978 SEM for ESX 
4 months, compared to 11.819 ± .858 SEM for H2O (p < .001), and .393 ± .932 SEM for 
ESX continuous (p = .003).  For seizure duration, there is no significant group effect, 
time effect, or time by group effect.  
ESX levels drawn from blood prior to perfusion of ESX continuous animals 




Figure 4.  Effect of early ESX treatment on seizure activity.  Percent time in SWD (A),  number of seizures 
per hour (B), and mean seizure duration (C) is shown based on analysis of EEG prior to ESX withdrawal (-
1 day) as well as 1, 14, 30, 60, and 90 days after ESX withdrawal in ESX 4 month rats ( ) and age-
matched H2O ( ) and ESX continuous ( ) groups.  Data is plotted as mean ± SEM.  Repeated-
measurements MANOVA with Wilks’ Lambda multivariate analysis, followed by Games-Howell posthoc 
analyses when appropriate revealed significant group, time, and time by group effects for percent time in 
SWD as well as number of seizures per hour (p < .05), but no significant group, time, or time by group 




 Total power spectrum analyses were also run for SWD and usable time for each 
experimental group pooled over timepoints 1 day through 90 days (Fig. 5A-F).  
Difference in power between groups for each frequency band was then calculated and 
Pearson correlation analysis was performed to compare each resulting curve to the 
seizure curve in H2O rats.  For the difference between H2O and ESX 4 month rats (Fig. 
5G), Pearson correlation equals 0.955, 2-tailed significance < .000000001, suggesting 
highly significant correlation.  For the difference between H2O and ESX continuous rats 
(data not shown), Pearson correlation equals 0.795, 2-tailed significance < .0001, also 
suggesting significant correlation.  For the difference between ESX 4 month and ESX 
continuous rats (Fig. 5H), Pearson correlation equals -0.259, 2-tailed significance = .300, 




Figure 5.  Power spectra.  Total power spectra for seizures (A-C) and all usable time (D-F) by group: H2O 
(top row), ESX 4 month (middle row), and ESX continuous (bottom row).  Data is plotted as mean ± SEM.  
(G) Difference between all usable power spectrum for H2O and ESX 4 month rats.  Pearson correlation 
analysis of this curve with the seizure curve shown in (A) equals 0.955, 2-tailed significance < .000000001.  
(H) Difference between all usable power spectrum for ESX 4 month and ESX continuous rats.  Pearson 
correlation analysis of this curve with the seizure curve shown in (A) was not significant.  For (G) and (H), 






 This study demonstrates that early seizure blockade prevents the abnormal 
expression of ion channels Nav1.1, Nav1.6, and HCN1 in WAG/Rij rat cortex and 
decreases seizure activity even after antiabsence medication is discontinued.  The 
combination of these data suggest that seizures may beget further seizures by altering 
levels of ion channels, and by producing other cellular and molecular changes, which 
then lead to increased membrane excitability and hence the propensity for seizure 
activity. 
 A number of questions result from this discovery.  Although the alteration of ion 
channels after treatment with ESX suggests that this may be the mechanism by which 
long-term seizure activity is altered, we have not yet shown that ion channel levels 
remain altered after ESX is stopped, or that ion channel levels are directly related to 
seizure frequency or duration.  Further experiments to elucidate this question could 
involve early measurement of cortical ion channel expression in rats that were sacrificed 
after the 90-day timepoint, and correlation of these levels with seizure activity prior to 
sacrifice. 
Our data show that treatment with ESX alters ion channel levels specifically in 
the cortex, and that early temporary ESX alters long-term seizure frequency but not 
duration.  Previous experiments have shown that seizures are initiated in WAG/Rij 
cortex, but thalamocortical networks are necessary for the maintenance of seizure activity 
[38].  Taken in combination, this information suggests the possibility that alterations in 
cortical ion channels may contribute to seizure initiation and hence frequency.  It would 
be interesting, therefore, to measure ion channel expression in the thalamus of our rats; 
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one might hypothesize that since seizure duration was not altered in our rats, ion channel 
levels would not be altered in the thalamus.  Interestingly, whereas seizure activity is 
associated with cortical decreases in HCN1 which persist through adulthood in WAG/Rij 
rats [49, 50, 52], epileptogenesis is associated with thalamic increases in HCN1 which 
are later followed by adaptive changes in Ih which serve to terminate synchronous 
network activity in GAERS rats [51, 53]. 
Along these lines, the specific action of the antiabsence drug should be noted.  
Blockade of thalamic T-type Ca2+ channels is often cited as the most likely mechanism of 
ESX activity [32], although a reduction of nonactivating Na+ current and Ca2+-activated 
K+ current in cortical and thalamic neurons likely contributes as well [33].  It would 
therefore be relevant to study the effects of other antiabsence drugs on ion channels and 
long-term seizure activity.  For example, expanding on our hypotheses regarding cortical 
effects on seizure frequency and corticothalamic effects on seizure duration, one could 
consider that medication acting predominantly on the thalamus would only limit seizure 
activity and channel alterations, whereas perhaps a medication with stronger cortical 
effects would be more likely to fully prevent seizure onset and hence channel alterations. 
Nav1.1, Nav1.6 and HCN1 are likely not the only channels involved in seizure 
generation and propagation.  For example, Ca2+ channel mutations likely underlies the 
expression of absence in mice [21, 54] and has been implicated for some forms of human 
absence epilepsy [21].  Presynaptic Cav2.1 channels are upregulated in the rostral 
reticular thalamic nucleus of 6-month-old WAG/Rij rats when compared to 
presymptomatic (3-month-old) WAG/Rij rats and age-matched non-epileptic ACI rats 
[55].    The TASK4 K+ channel has also shown positive linkage to human absence 
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epilepsy, and may contribute to absence epilepsy in GAERS rats as well [56].  
Additionally, the metabotropic glutamate mGlu2/3 receptor has been shown to be 
upregulated in the somatosensory cortex, ventrobasal thalamic nuclei, and hippocampus 
of 6-month-old WAG/Rij rats compared to nonepileptic ACI and 2-month-old pre-
epileptic WAG/Rij rats [57].  GABAB receptors have been implicated in determining 
neocortical excitability in WAG/Rij rats as well: mRNA levels for GABAB(1) subunits are 
diminished, these GABAB(1) subunits fail to localize to the distal dendrites of pyramidal 
cells, and paired-pulse depression is decreased in epileptic WAG/Rij neocortex compared 
to age-matched non-epileptic controls [58].  It would therefore be beneficial to study the 
effects of early temporary antiabsence treatment on some of these channels as well, to 
determine the role of these channels in begetting increased seizure activity.  Specifically, 
channels exhibiting the strongest correlation with long-term seizure activity could be 
directly targeted for preventative treatment. 
In addition to ion channels, other mechanisms that may be important for 
epileptogenesis should be studied as well.  Recurrent seizures induced by various 
mechanisms during early development in rodents have been shown to result in aberrant 
mossy fiber sprouting, reduced neurogenesis, and morphological changes in dendritic 
spines [3].  Additionally, it has been hypothesized that interictal spikes result in post-
injury epileptogenesis [59].  Experiments involving the prevention of these changes, 
either by seizure blockade, treatment of interictal spikes, or other mechanisms, will be 
helpful in determining which processes lead most strongly to epileptogenesis and 





The power spectrum analysis of our data raises interesting questions as well.  The 
difference between the power spectrum for usable data for H2O rats and that of ESX 4 
month rats correlates closely with the power spectrum of seizures in an untreated H2O rat.  
This correlation provides an additional objective measure of the increased seizure activity 
in H2O rats compared to ESX 4 month rats, since it does not require identification of 
individual seizures by either humans or by computer.  This data also suggests that 
quantification of power spectrum data may eventually be useful in determining the 
adequacy of preventative seizure treatments. 
Interestingly, the comparison of usable data for ESX 4 month rats compared to 
ESX continuous rats showed a peak at 2-3 Hz with a second, smaller peak at 9-10 Hz, 
which did not correlate significantly with the seizure power spectra.  One possible 
explanation for this is that ESX treatment at various timepoints may prevent synchronous 
activity in a variety of frequency bands, including but not limited to that of seizures.  
The generalizability of our absence seizure data to other types of seizures is 
another important issue.  It has been suggested that absence epilepsy is related to a 
predominance of inhibitory activity, whereas generalized convulsive and focal seizures 
are characterized by an excess of excitatory activity [12, 60].  This may explain why 
anticonvulsant drugs such as carbamazepine and diphenylhydantoin have no effect or 
even worsen absence seizure activity [11, 30].   As described in the introduction, many 
seizures-beget-seizures models involve experimental induction of convulsive seizures or 
status epilepticus, whereas our model involves prevention of spontaneous non-convulsive 
seizures.  It is possible that the excessive inhibitory activity in absence seizures actually 
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counters the tendency towards other types of excitatory brain activity.  For example, 
studies show that WAG/Rij rats are more resistant to amygdala kindling than Wistar rats 
[60], a kindling-resistant subpopulation of WAG/Rij rats shows significantly longer SWD 
durations compared with kindled WAG/Rij rats [60], and that GAERS rats are fully 
resistant to kindling [13, 61].  Further studies would therefore be necessary to determine 
the effects of early absence seizure blockade on later susceptibility to other seizure types. 
Along these lines, an interesting angle for our study comes from data suggesting 
that seizures are sensitive to environmental manipulations.  In one study, neonatal 
handling and maternal deprivation led to a decrease in absence seizures later in life as 
well as an increase in HCN1 protein and Ih [50].  On the other hand, rats exposed to 
neonatal isolation in addition to status epilepticus induced by lithium-pilocarpine at P10 
had prolonged seizure duration and increased seizure susceptibility compared to non-
isolated rats with induced status epilepticus [62].  These thought-provoking studies 
highlight the necessary balance between excitation and inhibition for normal 
development of the nervous system as well as the far-reaching effects of early 
environmental stimulation versus neglect on brain function.  Additionally, these studies 
suggest that the developing nervous system may be more sensitive to the effect of 
seizures, which may alter normal developmental expression patterns of ion channels and 
other molecules that regulate excitation and inhibition [2, 3]. 
Clinically, it is especially important to recognize the magnitude of the effect of 
both pharmacologic and environmental changes on nervous system development.  Our 
study may indicate that early treatment, perhaps even prior to the onset of clinical seizure 
activity for known genetic cases of absence epilepsy, would be beneficial in reducing 
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later epileptic activity.  However, it is important to note that whereas rats have increasing 
seizures with age [24], 70% of human absence epilepsy spontaneously remits around 
adolescence; the remaining 30% persists into adulthood and often coexists with other 
types of seizure activity [21].  The variability in the clinical outcome is likely related to 
the underlying molecular basis and type of absence epilepsy [21, 35, 36].  Whereas brain 
maturity occurs at P25-P35 in rodents (4-14 days after the start of ESX in our 
experiments), brain maturity occurs post-puberty in humans [4].  Further experiments 
involving earlier AED treatment in rodents might therefore help further elucidate the time 
course of alterations in ion channels and epileptogenicity.  Additionally, the effects of 
very early ESX treatment in humans is not known, although ESX exposure in utero has 
been associated with neonatal hemorrhage due to a deficiency of vitamin K dependent 
clotting factors [63].  Further investigation of these effects would therefore be necessary 
prior to recommending more aggressive early treatment for genetic absence epilepsy in 
humans.  Additionally, alternative agents should be explored where the effect may be 
related to the molecular basis of the absence epilepsy in patients.   
Overall, these data provide exciting new insights into the world of seizure 
development.  In the future, such information will likely prove useful in guiding the 
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